BMO Capital maintained an Outperform rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $192.00 (from $195.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Jazz Pharmaceuticals (JAZZ): Cutting PT ~30% - MizuhoNovember 9, 2016 6:23 AM After-Hours Movers 11/08: (SAEX) (ARTX) (GMED) Higher; (TRIP) (MPSX) (JAZZ) Lower (more...)November 8, 2016 6:05 PM Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c; Guides In-LineNovember 8, 2016 4:09 PM Jazz Pharmaceuticals Announces Third Quarter 2016 Financial ResultsNovember 8, 2016 4:05 PM Jazz Pharmaceuticals to Present New Data at the Annual ASH MeetingNovember 7, 2016 4:05 PM Trading Radar for 11/8: D. R. Horton (DHI), Valeant Pharma (VRX), CVS Health (CVS), Valvoline (VVV) ReportNovember 7, 2016 2:35 PM